Table 2.
Patient and treatment characteristics by use of antiepileptic drug
| Characteristic | No AED (n=128) | AED (n=403) | P value* | VA (n=29) | Non-VA AED (n=374) | P value* |
|---|---|---|---|---|---|---|
| Sex, n (%) | ||||||
| M | 72 (56.3) | 270 (67.0) | .027 | 16 (55.2) | 254 (67.9) | .16 |
| F | 56 (43.8) | 133 (33.0) | 13 (44.8) | 120 (32.1) | ||
| Age, y | ||||||
| Median | 57 | 56 | 53 | 56 | ||
| Age, n (%) | ||||||
| <50 | 37 (28.9) | 124 (30.8) | .993† | 10 (34.5) | 114 (30.5) | .54† |
| ≥50 | 91 (71.1) | 279 (69.2) | 19 (65.5) | 260 (69.5) | ||
| KPS, n (%) | ||||||
| ≥90 | 62 (48.4) | 190 (47.1) | .127 | 11 (37.9) | 179 (47.9) | .517 |
| ≥70 <90 | 56 (43.8) | 158 (39.2) | 13 (44.8) | 145 (38.8) | ||
| <70 | 8 (6.3) | 51 (12.7) | 5 (17.2) | 46 (12.3) | ||
| Mental status, n (%) | ||||||
| Normal | 108 (84.4) | 300 (74.4) | .025 | 19 (65.5) | 281 (75.1) | .154 |
| Abnormal | 18 (14.1) | 93 (23.1) | 10 (34.5) | 83 (22.2) | ||
| Data missing | 2 (1.6) | 10 (2.5) | 0 (0.0) | 10 (2.7) | ||
| Symptom length, n (%) | ||||||
| <12 wk | 98 (76.6) | 312 (77.4) | .306† | 22 (75.9) | 290 (77.5) | .621† |
| ≥12 wk | 30 (23.4) | 90 (22.3) | 7 (24.1) | 83 (22.2) | ||
| Data missing | 0 (0.0) | 1 (0.2) | 0 (0.0) | 1 (0.3) | ||
| Neurologic functional status, n (%) | ||||||
| Working | 54 (42.2) | 156 (38.7) | .503 | 11 (37.9) | 145 (38.8) | .858 |
| Not working | 72 (56.3) | 239 (59.3) | 18 (62.1) | 221 (59.1) | ||
| Data missing | 2 (1.6) | 8 (2.0) | 0 (0.0) | 8 (2.1) | ||
| RTOG RPA, n (%) | ||||||
| Class VI | 7 (5.5) | 31 (7.7) | .25 | 2 (6.9) | 29 (7.8) | .99 |
| Class V | 59 (46.1) | 149 (37.0) | 11 (37.9) | 138 (36.9) | ||
| Class IV | 36 (28.1) | 141 (35.0) | 11 (37.9) | 130 (34.8) | ||
| Class III | 24 (18.8) | 74 (18.4) | 5 (17.2) | 69 (18.4) | ||
| Unknown | 2 (1.6) | 8 (2.0) | 0 (0.0) | 8 (2.1) | ||
| Surgical extent, n (%) | ||||||
| Biopsy | 28 (21.9) | 49 (12.2) | .017 | 6 (20.7) | 43 (11.5) | .341 |
| STR | 49 (38.3) | 192 (47.6) | 12 (41.4) | 180 (48.1) | ||
| GTR | 51 (39.8) | 161 (40.0) | 11 (37.9) | 150 (40.1) | ||
| Radiation dose, n (%) | ||||||
| >54.4 Gy | 110 (85.9) | 330 (81.9) | .969† | 25 (86.2) | 305 (81.6) | .532† |
| ≤54.4 Gy | 15 (11.7) | 54 (13.4) | 4 (13.8) | 50 (13.4) | ||
| Data missing | 3 (2.3) | 19 (4.7) | 0 (0.0) | 19 (5.1) | ||
| Concurrent chemotherapy, n (%) | ||||||
| TMZ | 51 (39.8) | 134 (33.3) | .208 | 12 (41.4) | 122 (32.6) | .692 |
| Other chemotherapy‡ | 10 (7.8) | 50 (12.4) | 3 (10.3) | 47 (12.6) | ||
| None | 67 (52.3) | 221 (54.8) | 15 (51.7) | 206 (55.1) | ||
| Seizure before end of RT, n (%) | ||||||
| Yes | 4 (3.1) | 221 (54.8) | <.001 | 22 (75.9) | 189 (50.5) | .009 |
| No | 124 (96.9) | 191 (47.4) | 7 (24.1) | 184 (49.2) | ||
| Data missing | 0 (0.0) | 1 (0.2) | 0 (0.0) | 1 (0.3) | ||
Abbreviations: AED = antiepileptic drug; GTR = gross total resection; RTOG RPA = Radiation Therapy Oncology Group recursive partitioning analysis; STR = subtotal resection; TMZ = temozolomide.
*
χ2
†
t test.
‡
Other chemotherapy included carmustine, lomustine, procarbazine, vincristine, and cisplatin.